The results of the study show that when identifying the BMPR2 mutation, PAH manifests at a younger age, has a more severe course, and has an increased risk of death or lung transplantation compared to patients without the BMPR2 mutation [15]. The gene discussed is BMPR2; the disease is pulmonary arterial hypertension.